{
    "organizations": [],
    "uuid": "098879d4bf7611717232986bacb807f7144df18f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-accepts-supplemental-biolog/brief-u-s-fda-accepts-supplemental-biologics-license-application-for-opdivo-in-previously-treated-patients-with-small-cell-lung-cancer-idUSASC09WCW",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Opdivo In Previously Treated Patients With Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Bristol-Myers Squibb Co:\n* U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO (NIVOLUMAB) IN PREVIOUSLY TREATED PATIENTS WITH SMALL CELL LUNG CANCER AND GRANTS PRIORITY REVIEW\n* BRISTOL-MYERS SQUIBB - OPDIVO SUBMISSION BASED ON SAFETY AND EFFICACY DATA FROM SCLC COHORT OF PHASE 1/2 CHECKMATE -032 TRIAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T04:25:00.000+03:00",
    "crawled": "2018-04-19T14:58:36.026+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "squibb",
        "co",
        "food",
        "drug",
        "administration",
        "accepts",
        "supplemental",
        "biologics",
        "license",
        "application",
        "opdivo",
        "nivolumab",
        "previously",
        "treated",
        "patient",
        "small",
        "cell",
        "lung",
        "cancer",
        "grant",
        "priority",
        "review",
        "squibb",
        "opdivo",
        "submission",
        "based",
        "safety",
        "efficacy",
        "data",
        "sclc",
        "cohort",
        "phase",
        "checkmate",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}